Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prana ditches Alzheimer’s drug program
As part of the effort to manufacture GMP grade PBT1 (clioquinol) for clinical trials, Prana found unacceptably high levels of a di-iodo (toxic) form of PBT1. After further
As part of the effort to manufacture GMP grade PBT1 (clioquinol) for clinical trials, Prana found unacceptably high levels of a di-iodo (toxic) form of PBT1. After further
An approvable letter outlines specific questions that have to be resolved before the FDA will approve a product for marketing. The FDA’s questions in this letter relate specifically
Data from a multicenter, phase II trial of a Trisenox (arsenic trioxide) combination regimen, known as MAC (melphalan, Trisenox and vitamin C), were presented by Dr James Berenson,
Development of the compound was discontinued due to what the companies have described as “adverse findings” in on-going animal studies. Although this development program has been discontinued, Merck
Tracleer (bosentan), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hypertension (PAH) (WHO class III and IV) and made available by
The agreement covers the development of a sustained-release formulation of VasoGenix’s calcitonin gene related peptide (CGRP) using QLT’s Atrigel biodegradable sustained release drug delivery system. Under the terms
The study, published in CANCER, a peer-reviewed journal of the American Cancer Society, reports that concerns over the drug’s adverse effects were the primary reason for refusal. Tamoxifen,
Researchers in the fields of cardiovascular disease, rheumatism and multiple sclerosis (MS) from Karolinska Institutet and the Centre for Molecular Medicine (CMM) in Stockholm, Sweden have together shown
This study found that 71% of older adults used some form of alternative medicine in 2000. This appears to be a higher rate than occurs within the general
HIVNET 012, a trial conducted in Uganda in 1997, found that nevirapine (Boehringer Ingelheim’s Viramune) is effective and safe in preventing HIV transmission from mother to unborn child